Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Polyhomeotic-like protein 3 (PHC3) is a member of the Polycomb group protein family, acting as a component of the human Polycomb repressive complex 1 (PRC1)-related hPRC-H complex, mediating gene silencing through epigenetic regulation. PHC3 contains a (Cys)4-type zinc finger and a sterile alpha motif (SAM) domain, both important for protein-protein interactions involved in organizing higher-order chromatin structure and recruiting chromatin-remodeling complexes. PHC3 regulates the repression of transcription in quiescent (G₀) cells, interacting with other Polycomb proteins (such as YY1, M33, and Bmi1) and the transcription factor E2F6, with which it forms complexes that silence E2F and Myc target promoters. Loss-of-function mutations, loss of expression, and deletion of the PHC3 gene have been linked to human osteosarcoma, suggesting its role as a tumor suppressor gene. There is no current evidence for direct pharmacological targeting of PHC3, but its loss serves as a potential biomarker for predisposition to or progression of certain cancers[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Polyhomeotic-like protein 3 (PHC3).